Company intelligence / Profile preview

ExoVectory

Rotterdam, South Holland, Netherlands

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Company is in pre-clinical development stage, working towards in vivo proof of concept for glioblastoma treatment using exosome-packaged DNA constructs. Research has demonstrated widespread delivery in 3D cultured tumor cells and efficient spread through mouse brain.

Therapeutic areas: OncologyRare Diseases
Modalities: Exosome-based therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on ExoVectory.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoVectory.

Explore the full profile